Toll Free: 1-888-928-9744

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 329 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H1 2016', provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction
- The report reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Adenocarcinoma Of The Gastroesophageal Junction therapeutics and enlists all their major and minor projects
- The report assesses Adenocarcinoma Of The Gastroesophageal Junction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Adenocarcinoma Of The Gastroesophageal Junction Overview 8 Therapeutics Development 9 Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview 9 Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis 10 Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies 11 Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes 13 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies 17 Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes 20 Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development 21 AB Science SA 21 AbbVie Inc. 22 Advenchen Laboratories, LLC 23 Amgen Inc. 24 ArQule, Inc. 25 AstraZeneca Plc 26 Boehringer Ingelheim GmbH 27 Boston Biomedical, Inc. 28 Bristol-Myers Squibb Company 29 Cerulean Pharma, Inc. 30 Daiichi Sankyo Company, Limited 31 Dr. Reddy's Laboratories Limited 32 Eli Lilly and Company 33 F. Hoffmann-La Roche Ltd. 34 Ganymed Pharmaceuticals AG 35 Genentech, Inc. 36 Gilead Sciences, Inc. 37 Hutchison MediPharma Limited 38 Imugene Limited 39 Johnson & Johnson 40 Mebiopharm Co., Ltd. 41 MedImmune, LLC 42 Merck & Co., Inc. 43 Merck KGaA 44 Millennium Pharmaceuticals, Inc. 45 Novartis AG 46 Oncobiologics, Inc. 47 Panacea Biotec Limited 48 Sanofi 49 Taiho Pharmaceutical Co., Ltd. 50 Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Combination Products 52 Assessment by Target 53 Assessment by Mechanism of Action 56 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 (tipiracil hydrochloride + trifluridine) - Drug Profile 63 AL-3818 - Drug Profile 66 alisertib - Drug Profile 68 alpelisib - Drug Profile 73 AMG-337 - Drug Profile 75 atezolizumab - Drug Profile 76 avelumab - Drug Profile 81 AZD-4547 - Drug Profile 83 AZD-6738 - Drug Profile 85 BI-853520 - Drug Profile 87 cabazitaxel - Drug Profile 88 catumaxomab - Drug Profile 90 Cellular Immunotherapy for Oncology - Drug Profile 93 ceritinib - Drug Profile 94 CRLX-101 - Drug Profile 97 DS-8201 - Drug Profile 100 durvalumab - Drug Profile 101 durvalumab + tremelimumab - Drug Profile 106 emibetuzumab - Drug Profile 108 erdafitinib - Drug Profile 109 GS-5745 - Drug Profile 111 Her-VAXX - Drug Profile 113 ibrutinib - Drug Profile 115 IMAB-362 - Drug Profile 123 indusatumab vedotin - Drug Profile 125 ipatasertib - Drug Profile 127 ipilimumab - Drug Profile 129 LAG-525 - Drug Profile 134 LY-3127804 - Drug Profile 135 masitinib - Drug Profile 136 MBP-426 - Drug Profile 142 merestinib - Drug Profile 144 napabucasin - Drug Profile 145 panitumumab - Drug Profile 148 PDR-001 - Drug Profile 152 pembrolizumab - Drug Profile 153 pertuzumab - Drug Profile 164 ramucirumab - Drug Profile 168 SAR-408701 - Drug Profile 174 savolitinib - Drug Profile 175 solitomab - Drug Profile 178 sonidegib phosphate - Drug Profile 179 TAK-117 - Drug Profile 183 tivantinib - Drug Profile 184 trastuzumab biosimilar - Drug Profile 187 trastuzumab biosimilar - Drug Profile 189 trastuzumab biosimilar - Drug Profile 190 trastuzumab biosimilar - Drug Profile 191 tremelimumab - Drug Profile 192 Adenocarcinoma Of The Gastroesophageal Junction - Recent Pipeline Updates 195 Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects 316 Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products 317 Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones 318 Featured News & Press Releases 318 Appendix 324 Methodology 324 Coverage 324 Secondary Research 324 Primary Research 324 Expert Panel Validation 324 Contact Us 324 Disclaimer 325
List of Tables
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2016 13 Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Development by Companies, H1 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2016 24 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H1 2016 25 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc., H1 2016 26 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H1 2016 27 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H1 2016 28 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H1 2016 29 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H1 2016 30 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H1 2016 31 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H1 2016 32 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H1 2016 33 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H1 2016 34 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 35 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 36 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H1 2016 37 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 38 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H1 2016 39 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech, Inc., H1 2016 40 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H1 2016 41 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H1 2016 42 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H1 2016 43 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Johnson & Johnson, H1 2016 44 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H1 2016 45 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune, LLC, H1 2016 46 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H1 2016 47 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H1 2016 48 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 49 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H1 2016 50 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H1 2016 51 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H1 2016 52 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H1 2016 53 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 54 Assessment by Monotherapy Products, H1 2016 55 Assessment by Combination Products, H1 2016 56 Number of Products by Stage and Target, H1 2016 58 Number of Products by Stage and Mechanism of Action, H1 2016 61 Number of Products by Stage and Route of Administration, H1 2016 64 Number of Products by Stage and Molecule Type, H1 2016 66 Adenocarcinoma Of The Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H1 2016 199 Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H1 2016 320 Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H1 2016 321


List of Figures
Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H1 2016 13 Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 19 Assessment by Monotherapy Products, H1 2016 55 Assessment by Combination Products, H1 2016 56 Number of Products by Top 10 Targets, H1 2016 57 Number of Products by Stage and Top 10 Targets, H1 2016 57 Number of Products by Top 10 Mechanism of Actions, H1 2016 60 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 60 Number of Products by Routes of Administration, H1 2016 63 Number of Products by Stage and Routes of Administration, H1 2016 63 Number of Products by Molecule Types, H1 2016 65 Number of Products by Stage and Molecule Types, H1 2016 65

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify